Clinical trials: Total Neoadjuvant Therapy
Rectal Cancer, Adenocarcinoma of Rectum
ABCSG R07 Rectal Cancer Registry
In Austria, patients with rectal cancer that has not spread to other parts of the body are typically treated with either total neoadjuvant therapy (TNT) or immunotherapy, depending on their microsatellite status (DNA repair…
- Trial name
- ABCSG R07 RCR (NCT07780305)
- Where
- 6 sites in Austria
- Volunteers
- 600 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Esophageal Squamous Cell Carcinoma (ESCC)
Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC
Esophageal cancer is a malignant tumor with high incidence rate and mortality in China. According to the data of the World Health Organization, 324000 new cases and 301000 deaths of esophageal cancer will occur in China in 2020…
- Trial name
- NCT06861777
- Testing
- Adebrelimab + paclitaxel/nab-paclitaxel + cisplatin followed by chemoradiotherapy, chemoradiotherapy followed by adebrelimab + paclitaxel/nab-paclitaxel + cisplatin, TNT treatment [TNT group one (phase 2) or TNT group two (phase 2)]
- Where
- China
- Volunteers
- 474 people
- Sponsor
- YIN LI
Locally Advanced Rectal Cancer (LARC), Immunotherapy
Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study
The study is a multicenter, randomized controlled, phase III clinical study, and the purpose of the study is to explore the complete response rate (CR, Defined as pathological complete response (pCR) + Clinical complete response…
- Conditions
- Locally Advanced Rectal Cancer (LARC), Immunotherapy, Radiotherapy, Total Neoadjuvant Therapy
- Trial name
- NCT07020247
- Testing
- Anti-PD-1 antibody drug named Serplulimab, Radiotherapy, Chemotherapy
- Where
- China
- Volunteers
- 184 people
- Sponsor
- West China Hospital
Rectal Cancer
Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy
This is an open-label, multi-center, single-arm clinical study. All patients received 4-6 cycles total neoadjuvant therapy plus concurrent tislelizumab immunotherapy, then underwent clinical response assessment.
- Trial name
- TNTIT (NCT07561060)
- Testing
- Tislelizumab, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Plasma Cell Leukemia in Remission, Plasma Cell Myeloma
Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma
This phase I/II trial studies the side effects and best dose of melphalan and total marrow irradiation and how well they work with autologous stem cell transplantation in treating patients with high-risk multiple myeloma.
- Trial name
- NCT03100877
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Filgrastim
- Where
- United States
- Sponsor
- City of Hope Medical Center
Rectal Cancer
Total Neoadjuvant Therapy in Rectal Cancer Treatment
This is a randomized, controlled, parallel study to determine the efficiency and safety of total neoadjuvant therapy in rectal cancer treatment.
- Trial name
- NCT04747951
- Testing
- Concurrent Chemoradiotherapy, TME, consolidation chemotherapy
- Where
- Russia
- Volunteers
- 280 people
- Sponsor
- State Scientific Centre of Coloproctology, Russian Federation
Rectal Cancer, Radiotherapy
Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer
This is a open-label, single-arm study to investigate the safety and efficacy of Total neoadjuvant chemotherapy with camrelizumab, an anti-PD-1 antibody drug following short course radiotherapy in patients with rectal cancer.
- Conditions
- Rectal Cancer, Radiotherapy, Immunotherapy, Organ Preservation
- Trial name
- NCT04558684
- Testing
- Chemotherapy, Immunotherapy, IMRT
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Rectal Cancer, Adenocarcinoma, Locally Advanced Malignant Neoplasm
Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer
The benefit of aspirin in cancer of the colon and rectum is already known. Recently, it was described its potential activity during chemoradiotherapy, with higher rate of tumor downstaging.
- Conditions
- Rectal Cancer, Adenocarcinoma, Locally Advanced Malignant Neoplasm, Chemoradiation
- Trial name
- ICAR (NCT03170115)
- Testing
- Aspirin
- Where
- Brazil
- Volunteers
- 25 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
Rectal Neoplasms, Rectal Adenocarcinoma
A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer
This study aims to evaluate the safety and effectiveness of a combination treatment including a PD-1 inhibitor (serplulimab), oncolytic virus H101, short-course radiotherapy, and XELOX chemotherapy as total neoadjuvant therapy in…
- Trial name
- NCT07543848
- Testing
- Serplulimab, Oncolytic Virus H101, XELOX Chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chongqing University Cancer Hospital
Rectal Cancer
Total Neoadjuvant Therapy Versus Standard Therapy of Locally Advanced Rectal Cancer With High Risk Factors for Failure
In a retrospective study, the investigators will compare patients with locally advanced rectal cancer with high risk factors for failure who were treated with standard therapy or with total neoadjuvant therapy.
- Trial name
- NCT04679597
- Testing
- Capecitabine
- Volunteers
- 161 people
- Sponsor
- Institute of Oncology Ljubljana
Rectal Cancer
TaTME Versus Open Intersphincteric Resection After Neoadjuvant Concurrent Chemoradiotherapy.
The two surgical options for lower 1/3 rectal cancer is APR and sphincter sparing procedures. Intersphincteric resection is procedure to treat very low rectal cancer within 2 cm from the dentate line to avoid permanent…
- Trial name
- TaTME (NCT01836926)
- Testing
- Open intersphincteric resection, transanal minimally invasive intersphincteric resection
- Where
- 2 sites in Egypt
- Volunteers
- 110 people
- Sponsor
- Osama Mohammad Ali ElDamshety
Locally Advanced Low Rectal Adenocarcinoma, pMMR (Microsatellite Stable Rectal Cancer)
PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer
The goal of this clinical trial is to find out if adding a PD-1 antibody (serplulimab) to FOLFOXIRI chemotherapy and radiotherapy works better than CAPOX chemotherapy with radiotherapy as total neoadjuvant therapy for adults with…
- Trial name
- NCT07277842
- Testing
- Serplulimab, FOLFOXIRI chemotherapy, CAPOX chemotherapy
- Where
- China
- Volunteers
- 382 people
- Sponsor
- Sun Yat-sen University
Locally Advanced Rectal Cancer (LARC)
AI-Based Prediction of Pathological Response in Rectal Cancer Patients Receiving Total Neoadjuvant Therapy
This study aims to better understand how body composition, inflammation, and nutrition affect how rectal cancer responds to treatment.
- Trial name
- CINR-AI (NCT07049627)
- Testing
- Total Neoadjuvant Therapy (TNT)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 93 people
- Sponsor
- Ankara Etlik City Hospital
Tislelizumab, Locally Advanced Rectal Cancer
Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer
There have been many high-quality research publications, including the TNT model of short-term radiotherapy combined with consolidation chemotherapy, and the TNT model of three-drug combination with neoadjuvant chemotherapy with…
- Conditions
- Tislelizumab, Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment, PD-1
- Trial name
- STARS-RC03 (NCT04906044)
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- The First Hospital of Jilin University
Locally Advanced Rectal Adenocarcinoma
Study Evaluating Two Treatment Strategies for Rectal Cancer in Patients ≥75 Years Old
The primary objective of the NACRE-2 trial is to assess whether the addition of chemotherapy after short-course radiotherapy is more effective than short-course radiotherapy alone in elderly patients with locally advanced rectal…
- Trial name
- NACRE-2 (NCT07118800)
- Testing
- FOLFOX4s, Short Course Radiotherapy
- Volunteers
- 160 people
- Sponsor
- UNICANCER
Pancreatic Ductal Adenocarcinoma
A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
The researchers are doing this study to find out whether using the chemotherapy regimen NALIRIFOX in combination with ablative dose radiation therapy (AD-XRT) and the standard chemotherapy drug capecitabine is an effective…
- Trial name
- NCT05851924
- Testing
- NALIRIFOX, AD-XRT and Capecitabine
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Rectal Neoplasm Malignant
Metabolomics to Predict Treatment Response and Toxicities in Rectal Cancer
Background: Colorectal cancer is the leading cause of cancer-related deaths in Taiwan, with rectal cancer accounting for approximately 27% of all cases.
- Trial name
- NCT06831669
- Testing
- Collecting biospecimens
- Where
- Taiwan
- Volunteers
- 250 people
- Sponsor
- Chang Gung Memorial Hospital
Stage III and IV Ovarian Cancer
Total Neoadjuvant 6 Cycles of Chemotherapy Versus 3 Cycles in Partial Responder Patients Diagnosed With Epithelial Ovarian Cancer
neoadjuvant chemotherapy in stage III and IV ovarian cancer is given in 3-4 cycles with patients who R0 surgical resection is less likely to occur, in this study will assess total neoadjuvant chemotherapy 6 cycles then interval…
- Trial name
- NCT06980545
- Testing
- Neoadjuvant chemotherapy (Paclitaxel and Carboplatin)
- Volunteers
- 50 people
- Sponsor
- Assiut University
Gastric Cancer, Stomach Cancer
Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer
The main goal of this study is to investigate the proportion of participants with locally advanced gastric and gastroesophageal adenocarcinoma without previous treatment during the last 5 years who can tolerate all planned cycles…
- Conditions
- Gastric Cancer, Stomach Cancer, GastroEsophageal Cancer, Gastric Adenocarcinoma
- Trial name
- OCTASUR (NCT06028737)
- Testing
- Docetaxel, Oxaliplatin, Leucovorin
- Where
- 2 sites in Lithuania, Ukraine
- Volunteers
- 150 people
- Sponsor
- Ukrainian Society of Clinical Oncology
Esophagogastric Adenocarcinoma
TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma
This trial is designed to evaluate a total neoadjuvant approach using D-FLOT as the new standard backbone in patients with resectable esophagogastric adenocarcinoma.
- Trial name
- NCT07507968
- Testing
- Durvalumab
- Where
- 29 sites in Germany, Spain
- Volunteers
- 101 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest